How Does Genetic Blood Testing Work in Pregnancy?

Learn how genetic blood testing (NIPT) works in pregnancy. Discover cfDNA analysis, fetal fraction, and accuracy for common conditions. Expert guide for.

Genetic blood testing in pregnancy, also known as noninvasive prenatal testing (NIPT), works by analyzing small fragments of cell-free fetal DNA (cfDNA) circulating in the mother's bloodstream. This screening method, widely available Today, detects the presence of extra or missing chromosomes—such as trisomy 21 (Down syndrome), trisomy 18, and trisomy 13—with high accuracy. Unlike invasive procedures like amniocentesis, NIPT requires only a simple maternal blood draw, posing no risk to the fetus. The test is typically performed after 10 weeks of gestation and can also reveal the baby's sex and, in some cases, microdeletion syndromes.

What Is Genetic Blood Testing in Pregnancy?

Genetic blood testing, often called NIPT or cfDNA screening, is a prenatal screening tool that evaluates the risk of certain chromosomal abnormalities. It is not diagnostic; a positive result requires confirmation through chorionic villus sampling (CVS) or amniocentesis. The test leverages the natural presence of fetal DNA fragments that cross the placenta into the maternal circulation. Today, improvements in sequencing technology and bioinformatics have increased detection rates for common aneuploidies to over 99% for trisomy 21, with false-positive rates below 0.1%.

Cell-Free Fetal DNA (cfDNA) Explained

During pregnancy, a small percentage of the DNA in a mother's blood comes from the placenta—this is cell-free fetal DNA. The placenta's cells release DNA fragments into the maternal bloodstream as they turn over. The fetal fraction, typically ranging from 4% to 20% after 10 weeks, is critical for accurate analysis. If the fetal fraction is too low, the test may fail or yield inconclusive results. Laboratories use next-generation sequencing (NGS) or microarray-based methods to count the number of fragments from each chromosome, comparing the ratio of fetal to maternal DNA to detect aneuploidies.

The Step-by-Step Process of NIPT

Understanding the workflow helps expectant parents know what to expect. Here is a typical sequence:

• Blood draw: A healthcare provider collects a standard blood sample from the mother's arm, usually 10–20 mL.
• Laboratory processing: The sample is centrifuged to separate plasma, which contains cfDNA. DNA is extracted and amplified.
• Sequencing or array analysis: The DNA fragments are sequenced or hybridized to probes that target specific chromosome regions. Automated algorithms count the number of reads per chromosome.
• Risk calculation: Using proprietary software, the lab computes a risk score (e.g., 1 in 10,000) for each condition. Results are typically available within 7–10 business days.
• Result reporting: The report indicates whether the result is “low risk” (negative) or “high risk” (positive) for the screened conditions. A high-risk result does not confirm a diagnosis—it indicates the need for follow-up diagnostic testing.

What Conditions Does Genetic Blood Testing Screen For?

Most NIPT panels today screen for the following common chromosome abnormalities. The table below shows the conditions and typical detection rates.

Note that detection rates vary by laboratory and the specific technology used. Always discuss the panel’s scope with your provider.

Accuracy and Limitations of NIPT (Update)

While NIPT is highly accurate for common trisomies, it is not perfect. False positives can occur due to confined placental mosaicism (where the placenta has an abnormal chromosome pattern but the fetus is normal), vanishing twin syndrome, or maternal conditions such as cancer. False negatives are rare but possible if the fetal fraction is low or if the abnormality is not present in the placental DNA. The American College of Obstetricians and Gynecologists (ACOG) recommends that all women be offered NIPT regardless of age or risk factors. Today, expanded NIPT panels also include screening for rare autosomal trisomies and copy number variants, though clinical utility is still being evaluated. It is essential to understand that NIPT is a screening test—not a diagnosis. A positive result should always be followed by diagnostic confirmation.

Frequently Asked Questions

Below are common questions about genetic blood testing in pregnancy, answered by our experts.

If you are considering genetic blood testing during your pregnancy, talk to your healthcare provider about whether NIPT is right for you. For a complete overview of available screening options and to order a test directly, visit our order page. Ready to learn more? Order your NIPT screening today at prenatalscreenings.com/order/nipt.